Clinical trial data published this week indicates significant progress in delivering targeted RNA therapeutics directly to liver tissue via advanced lipid nanoparticles. The approach demonstrates a 40% reduction in circulating metabolic biomarkers associated with rare genetic liver conditions, outperforming previous synthetic delivery vectors.
Manufacturing Scalability Achieved
Contract development and manufacturing organizations report that microfluidic formulation processes have reduced batch variance by 28%. This manufacturing milestone allows biopharmaceutical firms to transition from lab-scale synthesis to commercial-grade output rapidly.